Medtronic receives FDA approval for SynchroMed III system
Medtronic has received U.S. Food and Drug Administration (FDA) approval of its next-generation SynchroMed III intrathecal drug delivery system for patients with chronic pain, cancer pain, and severe spasticity. SynchroMed III is a targeted drug delivery (TDD) platform that alleviates symptoms by delivering medication directly to the fluid surrounding the spinal cord. SynchroMed III is an upgraded system compared to the SynchroMed II system, featuring a new "refill only" physician work...
Source: huewire.com